Jereb B, Us-Krasovec M, Cervek J, Soos E
Institute of Oncology, Ljubljana, Yugoslavia.
J Interferon Res. 1987 Aug;7(4):357-63. doi: 10.1089/jir.1987.7.357.
Seven patients with ipsilateral pleural carcinomatosis from breast cancer were treated by intrapleural application of a crude interferon-alpha (IFN-alpha) preparation (HLI). In 4 patients, previous systemic treatment had been without effect, and 3 patients had recurrence after initial remission. Pleural carcinomatosis was confirmed by cytology in 6 patients and by histology in 1 patient. HLI was given in doses of 2.2 X 10(6) IU two to six times. The effect was evaluated by cytological examination of the pleural fluid; malignant cells disappeared in all six patients who were evaluable. Pleural fluid, while not totally resolving, did not accumulate further after HLI. Disseminated tumor was present in all at the time of eventual death. No tumor was found in the pleura at autopsy of 2 patients and the pleural fluid was free of malignant cells at the time of last follow-up examination in the 4 others. These results seem to justify further investigation on larger groups of patients with better technique of application.
7例患有同侧乳腺癌胸膜转移癌的患者接受了胸膜内注射粗制α-干扰素（IFN-α）制剂（HLI）的治疗。4例患者先前的全身治疗无效，3例患者在初始缓解后复发。6例患者通过细胞学检查确诊为胸膜转移癌，1例通过组织学检查确诊。HLI的给药剂量为2.2×10(6) IU，给药2至6次。通过对胸腔积液的细胞学检查评估疗效；所有6例可评估的患者中恶性细胞均消失。胸腔积液虽未完全消退，但在注射HLI后未进一步积聚。所有患者最终死亡时均存在播散性肿瘤。2例患者尸检时胸膜未发现肿瘤，另外4例患者在最后一次随访检查时胸腔积液中无恶性细胞。这些结果似乎证明有必要采用更好的给药技术对更多患者群体进行进一步研究。
